研究单位：[1]Jiangsu HengRui Medicine Co., Ltd.[2]Qilu Hospital of Shandong University [3]Gansu Provincial Hospital,Lanzhou, Gansu, China[4]The Fourth Hospital of Hebei Medical University,Shijiazhuang, Hebei, China[5]The Second Xiangya Hospital of Central South University,Changsha, Hunan, China[6]The Second Affiliated Hospital of Soochow University,Suzhou, Jiangsu, China[7]Northern Jiangsu People's Hospital,Yangzhou, Jiangsu, China, 225001[8]Shengjing Hospital of China Medical University,Shenyang, Liaoning, China, 110004[9]Qilu Hospital of Shandong University,Jinan, Shandong, China, 250012[10]Taizhou Hospital,Taizhou, Zhejiang, China[11]Xuan Wu hospital affiliated to Capital Medical University,Beijing, China, 100053[12]Beijing Tongren hospital affiliated to Capital Medical University,Beijing, China, 11691777[13]Longhua Hospital Shanghai University of Traditional Chinese Medicine,Shanghai, China
The aim of present study is to evaluate the efficacy and safety of Extended-Release Carvedilol Sulfate versus in Patients With Mild or Moderate Primary Hypertension
